Momecort (Mometasone Furoate Monohydrate)

Mometasone furoate monohydrate, the active ingredient in Momecort, is a corticosteroid presented as a nasal spray for intranasal use. It is indicated for the management of allergic rhinitis and nasal polyps in appropriate patient populations. GNH USA supplies Momecort as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Momecort is a nasal corticosteroid that reduces inflammation in the upper airway. - Allergic rhinitis: relieves nasal congestion, itching and sneezing caused by allergic inflammation. - Nasal polyps: helps shrink polyps and improves nasal airflow. - Seasonal allergic rhinitis: controls symptoms during pollen seasons by decreasing mucosal swelling.

Momecort may cause local and systemic adverse reactions, most of which are mild and reversible.

Common Side Effects: - Nasal irritation or burning sensation - Dryness of the nasal mucosa - Epistaxis (nosebleeds) - Headache - Altered taste or bitter taste - Throat irritation or cough

Serious or Rare Side Effects: - Nasal septal perforation - Severe allergic reaction (anaphylaxis) - Vision changes such as cataracts or glaucoma - Adrenal suppression with prolonged high‑dose use - Opportunistic fungal infection of the nasal passages

Before initiating therapy, consider the following safety measures. - Assess for active nasal infection: avoid use in untreated bacterial or fungal sinusitis. - Avoid concurrent use with other intranasal corticosteroids to prevent excess systemic exposure. - Monitor growth in pediatric patients during long‑term treatment. - Use with caution in patients with glaucoma or cataracts. - Do not use in individuals with known hypersensitivity to mometasone or excipients. - Store at room temperature: keep in the original container, protect from moisture and direct heat.

Momecort can interact with other medicines that affect corticosteroid metabolism or systemic exposure.

Major Interactions (Avoid): - Systemic corticosteroids: increase risk of systemic glucocorticoid effects. - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, ritonavir): may raise local drug levels. - Antifungal azoles used systemically: potential for enhanced steroid activity.

Moderate Interactions (Monitor Closely): - Moderate CYP3A4 inhibitors (e.g., erythromycin, fluconazole): may modestly increase exposure. - Immunosuppressants (e.g., cyclosporine): monitor for additive immunosuppression. - Nasal decongestants: may mask underlying infection, use with clinical judgment.